Related Announcements

PA-20-272 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

Issued by

National Institute of General Medical Sciences (NIGMS)

All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The following NIH Offices may co-fund applications assigned to those Institutes/Centers.

Office of Research on Women's Health (ORWH)

Purpose

The National Institute of General Medical Sciences (NIGMS) announces the availability of funds for administrative supplements to Institutional Development Award (IDeA) Networks of Biomedical Research Excellence (INBRE) (P20) awards. These funds are intended for existing INBREs to develop collaborations between investigators at the INBRE partner institutions and investigators supported by one of the following programs:

• Centers of Biomedical Research Excellence (COBRE)
• IDeA Networks for Clinical and Translational Research (IDeA-CTR)
• IDeA co-funded R01s and R15s
• IDeA States Pediatric Clinical Trials Network (ISPCTN)
• National Center for Advancing Translational Sciences (NCATS) Clinical and Translational Science Awards (CTSA) to institutions located in IDeA states
• Native American Research Centers for Health (NARCH) awards to organizations located in IDeA states

The goal of this supplement program is to encourage collaborations among investigators in IDeA states while providing students a broad continuum of research opportunities. In-state collaboration is encouraged, although collaborative projects can also be proposed between programs that span IDeA states. Grant funds awarded to an IDeA-eligible institution may not be transferred via subcontract to an institution in a non-IDeA state.

The collaborative project should address new research objectives in addition to those currently supported by a COBRE, IDeA-CTR, IDeA co-funded R01s and R15s, ISPCTN, CTSA or NARCH award. The project must not constitute a change in scope of the parent award.

For these supplements, the INBRE must be active when the application is submitted (i.e., within the originally reviewed and approved project period), regardless of the time remaining on the current project. This applies also to programs that will collaborate with INBREs.

Application and Submission Information

Applications by INBRE awardees must be submitted to PA-20-272, "Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin. Supp. Clinical Trial Optional)" or its subsequent reissuance by the application due date.

All instructions in the SF424 (R&R) Application Guide and PA-20-272 (or its subsequent reissuance) must be followed, with the following additions:

• Application Due Dates – January 31, 2022; January 31, 2023; January 31, 2024; by 5:00 PM local time of applicant organization.
• For funding consideration, applicants must include “NOT-GM-22-001” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.
• Only one supplement request per INBRE will be accepted for each application due date.
• Requests may be for one year of support only.
• Requests can be no more than $120,000 in direct costs exclusive of Facilities and Administrative costs on sub-contracts. No more than 50% of the request can go to the collaborator(s) supported by the eligible collaborating program. As this is a 1-year supplement with a limited budget ($120,000 direct costs), a focused collaborative project rather than multiple collaborative projects is encouraged. As part of the budget justification, a statement regarding the expenditure of currently available unobligated grant funds for the INBRE should be included. Supplements may provide support above the established dollar limit for the parent grant award.
• The Research Strategy section of the application is limited to 6 pages.
  • The Research Strategy must clearly describe the significance of the project and the nature of the collaboration.
  • The Approach section of the Research Strategy should include two 2-page subsections, each prepared by the investigator(s) from the INBRE partner institution and the investigator(s) supported by the eligible collaborating program to describe their respective plans.
  • The Research Strategy section should include a description of how students from the INBRE partner institution will be included in the collaborative research project proposed.
• The application should include Letters of Support from the INBRE PD/PI and the collaborating program PD/PI detailing mentoring plans and resources that will be available to support the collaboration.

Reporting

Recipients will be required to include progress on the supplement project in the INBRE RPPR. The progress report should include information on scientific accomplishments, publications, collaborative grant applications submitted, and student involvement and their scholarly activities enabled by this award. The information will be used to assess the effectiveness of this award to develop inter-program collaborations at the INBRE partner institutions. If necessary, PD/PIs may be contacted after the completion of the grant period for updates on subsequent outcomes.

Applicants are strongly encouraged to review the Frequently Asked Questions (FAQs) related to this supplement posted on the DRCB INBRE webpage. Applicants should notify the contact listed below that a request has been submitted in response to this NOSI in order to facilitate efficient processing of the request.

Inquiries

Please direct all inquiries to:

Yang Zhou, PhD
National Institute of General Medical Sciences (NIGMS)
Email:yang.zhou@nih.gov